StockData
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Inc. (DRUG) stock

DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Sep 30, 2025Last filing: 40-F on Dec 23, 2025Score 5/30
$20.51−2.10 (-9.29%)

Close on Nov 17, 2026Market cap $156.61MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2025

Valuation

Market cap
C$223.26M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Trading

Previous close
$22.61
Open
$22.22
Day's range
$19.86 – $22.48
Volume
181,089
Average volume (20 days)
291,803
Index membership
Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
RSI (14 days)
26.5
Volatility (1 year)
86.1%
Relative volume
0.98×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodDRUGS&P 500DifferenceDRUG per yearS&P 500 per year
1 month-60.0%-4.0%−56.0 pts
3 months-74.2%-5.0%−69.2 pts
Year to date-73.7%+8.2%−82.0 pts
1 year-64.6%+11.2%−75.9 pts
3 years+1519.8%+68.5%+1451.3 pts+153.0%+19.0%
5 years-16.5%+67.3%−83.7 pts-3.5%+10.8%

Eight years at a glance

Fiscal years 2018 to 2025, CAD

EPS, diluted

–
Reported period

Press releases

Releases Bright Minds Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Bright Minds Biosciences

Pharmaceutical Preparations

Bright Minds Biosciences Inc. operates as a Canadian biotechnology and pharmaceutical company classified under pharmaceutical preparations. The provided text indicates that the enterprise conducts its activities alongside wholly owned subsidiaries. However, specific operational segments, proprietary therapeutic products or clinical pipeline assets, distinct commercial services, and identified customer groups are not detailed within the excerpted filing text. The entity focuses on administrative, governance, and regulatory compliance functions necessary for maintaining public reporting requirements across relevant capital oversight frameworks.

Company profile, executives and history

Bright Minds Biosciences stock: common questions

What is Bright Minds Biosciences's stock price?

DRUG closed at $20.51 on Nov 17, 2026, down 9.29% on the day.

What is Bright Minds Biosciences's market cap?

Bright Minds Biosciences was worth $156.61M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

Does Bright Minds Biosciences pay a dividend?

No. Bright Minds Biosciences has not paid a cash dividend over the last twelve months.

How has DRUG stock performed over the past year?

Including dividends, DRUG returned -64.6% over the past year, against +11.2% for the S&P 500.

Who are Bright Minds Biosciences's competitors?

Companies most similar to Bright Minds Biosciences by business, industry and size include NGEN, MSLE, HELP, CMND, BHST.

See a number that looks wrong?